Article

Ocriplasmin gains first Asian approval in Malaysia

ThromboGenics’ ocriplasmin (Jetrea) as been approved in Malaysia for the treatment of adults with vitreomacular traction (VMT).

 

Leuven, Belgium-ThromboGenics’ ocriplasmin (Jetrea) as been approved in Malaysia for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 µm.

The approval is the first in Asia and was gained following a Priority Review that was granted in September.

“The approval of (ocriplasmin) in Malaysia-the first in Asia-is a further important milestone in ensuring the global availability of this novel medicine,” said Patrik De Haes, MD, chief executive officer of ThromboGenics. “We are optimistic that, in time, (the drug) will become the treatment of choice for the earlier treatment of patients with VMT in Asia.”

ThromboGenics’ licensing partner, Alcon Laboratories, holds the commercialization rights to the drug outside the United States, and will be responsible for its launch in Malaysia.

Alcon, a division of Novartis, acquired the rights to commercialize the drug outside the United States in March 2012, and has already launched it in Europe and Canada.

 

ThromboGenics is commercializing the drug in the United States where it is approved for the treatment of patients with symptomatic vitreomacular adhesion.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.